866-997-4948(US-Canada Toll Free)

Obstructive Sleep Apnea - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 49 Pages

Obstructive Sleep Apnea - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obstructive Sleep Apnea Pipeline Review, H2 2016, provides an overview of the Obstructive Sleep Apnea (Respiratory) pipeline landscape.

Obstructive sleep apnea is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. Signs and symptoms of obstructive sleep apnea include excessive daytime sleepiness, awakening with chest pain, morning headache, high blood pressure, awakening with a dry mouth. Risk factors include being overweight, hypertension, diabetes, gender, smoking and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obstructive Sleep Apnea Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obstructive Sleep Apnea (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.Obstructive Sleep Apnea.

Obstructive Sleep Apnea (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obstructive Sleep Apnea (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obstructive Sleep Apnea (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obstructive Sleep Apnea (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obstructive Sleep Apnea (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Obstructive Sleep Apnea Overview 6
Therapeutics Development 7
Pipeline Products for Obstructive Sleep Apnea - Overview 7
Obstructive Sleep Apnea - Therapeutics under Development by Companies 8
Obstructive Sleep Apnea - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Obstructive Sleep Apnea - Products under Development by Companies 12
Obstructive Sleep Apnea - Companies Involved in Therapeutics Development 13
Galleon Pharmaceuticals Inc 13
RespireRx Pharmaceuticals Inc 14
SK Biopharmaceuticals Co Ltd 15
Vivus Inc 16
Obstructive Sleep Apnea - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 25
(phentermine + topiramate) ER - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
dronabinol - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
GAL-475 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GAL-475 Backups - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
SKL-N05 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Obstructive Sleep Apnea - Dormant Projects 38
Obstructive Sleep Apnea - Discontinued Products 39
Obstructive Sleep Apnea - Product Development Milestones 40
Featured News & Press Releases 40
Sep 26, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea 40
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 40
Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 41
May 14, 2015: VIVUS Announces Scientific Presentations 42
May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 43
Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 43
Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 44
Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa 45
Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 46
Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Obstructive Sleep Apnea - Pipeline by Galleon Pharmaceuticals Inc, H2 2016 13
Obstructive Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016 14
Obstructive Sleep Apnea - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 15
Obstructive Sleep Apnea - Pipeline by Vivus Inc, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Assessment by Combination Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 24
Obstructive Sleep Apnea - Dormant Projects, H2 2016 38
Obstructive Sleep Apnea - Discontinued Products, H2 2016 39

List of Figures
Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Top 10 Targets, H2 2016 19
Number of Products by Stage and Top 10 Targets, H2 2016 19
Number of Products by Top 10 Mechanism of Actions, H2 2016 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *